1. Buchanan KD, Johnston CF, O'Hare MM, Ardill JE, Shaw C, Collins JS, Watson RG, Atkinson AB, Hadden DR, Kennedy TL, .: Neuroendocrine tumors. A European view. Am J Med 81:14-22, 1986
2. BIORCK G, AXEN O, THORSON A: Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency. Fatal outcome after angiocardiography. Am Heart J 44:143-148, 1952
3. Davis Z, Moertel CG, McIlrath DC: The malignant carcinoid syndrome. Surg Gynecol Obstet 137:637-644, 1973
4. Solcia E, Capella C BR: Morphological and functional classification of endocrine cells and related growths in the gastrointestinal tract. Gastrointestinal Hormones 1: 1980
5. Weil C: Gastroenteropancreatic endocrine tumors. Klin Wochenschr 63:433-459, 1985
6. Carney JA, Go VL, Fairbanks VF, Moore SB, Alport EC, Nora FE: The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy. Ann Intern Med 99:761-766, 1983
7. Wynick D, Williams SJ, Bloom SR: Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 319:605-607, 1988
8. Eckhauser FE, Lloyd RV, Thompson NW, Raper SE, Vinik AI: Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery 104:1046-1053, 1988
9. Vinik A, Moattari AR: Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 34:14S-27S, 1989
10. Cameron SJ, Doig A: Cerebellar tumours presenting with clinical features of phaeochromocytoma. Lancet 1:492-494, 1970
11. Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE: Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A 83:3500-3504, 1986
12. Simpson S, Vinik AI, Marangos PJ, Lloyd RV: Immunohistochemical localization of neuron-specific enolase in gastroenteropancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase. Cancer 54:1364-1369, 1984
13. Kolby L, Bernhardt P, Sward C, Johanson V, Ahlman H, Forssell-Aronsson E, Stridsberg M, Wangberg B, Nilsson O: Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 120:269-273, 2004
14. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G, Borson-Chazot F: Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 60:644-652, 2004
15. De Block CE, Colpin G, Thielemans K, Coopmans W, Bogers JJ, Pelckmans PA, Van Marck EA, Van H, V, Martin M, De Leeuw IH, Bouillon R, Van Gaal LF: Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. Diabetes Care 27:1387-1393, 2004
16. Woltering EA, Hilton RS, Zolfoghary CM, Thomson J, Zietz S, Go VL, Vinik AI, Vinik E, O'Dorisio TM, Mamikunian G: Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas 33:250-254, 2006
17. Chaudhry A, Oberg K, Wilander E: A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 13:27-35, 1992
18. Turner GB, Johnston BT, McCance DR, McGinty A, Watson RG, Patterson CC, Ardill JE: Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 55:1586-1591, 2006
19. Chatziioannou A, Kehagias D, Mourikis D, Antoniou A, Limouris G, Kaponis A, Kavatzas N, Tseleni S, Vlachos L: Imaging and localization of pancreatic insulinomas. Clin Imaging 25:275-283, 2001
20. Gould M, Johnson RJ: Computed tomography of abdominal carcinoid tumour. Br J Radiol 59:881-885, 1986
21. Kressel HY: Strategies for magnetic resonance imaging of focal liver disease. Radiol Clin North Am 26:607-615, 1988
22. Eriksson B, Bergstrom M, Lilja A, Ahlstrom H, Langstrom B, Oberg K: Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 32:189-196, 1993
23. Eriksson B, Lilja A, Ahlstrom H, Bjurling P, Bergstrom M, Lindner KJ, Langstrom B, Oberg K: Positron-emission tomography as a radiological technique in neuroendocrine gastrointestinal tumors. Ann N Y Acad Sci 733:446-452, 1994
24. Sisson J, Shapiro B, Beierwaltes WH, Nakajo M, Glowniak J, Mangner T, Carey JE, Swanson DP, Copp J, Satterlee W, .: Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans Assoc Am Physicians 96:209-217, 1983
25. Fischer M, Kamanabroo D, Sonderkamp H, Proske T: Scintigraphic imaging of carcinoid tumours with 131I-metaiodobenzylguanidine. Lancet 2:165, 1984
26. Marx SJ, Vinik AI, Santen RJ, Floyd JC, Jr., Mills JL, Green J: Multiple endocrine neoplasia type I: assessment of laboratory tests to screen for the gene in a large kindred. Medicine (Baltimore) 65:226-241, 1986
27. Geatti O, Shapiro B, Sisson JC, Hutchinson RJ, Mallette S, Eyre P, Beierwaltes WH: Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 26:736-742, 1985
28. Lumbroso J, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Lemerle J, Parmentier C: [Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: analysis of 115 cases]. Bull Cancer 75:97-106, 1988
29. Treuner J, Feine U, Niethammer D, Muller-Schaumburg W, Meinke J, Eibach E, Dopfer R, Klingebiel T, Grumbach S: Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1:333-334, 1984
30. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y: Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321-1325, 1994
31. O'Steen WK, Barnard JL, Jr., Yates RD: Morphologic changes in skeletal muscle induced by serotonin treatment: a light- and electron-microscope study. Exp Mol Pathol 7:145-155, 1967
32. Frolich JC, Bloomgarden ZT, Oates JA, McGuigan JE, Rabinowitz D: The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 299:1055-1057, 1978
33. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van HM, Postema PT, de JM, Reubi JC, .: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731, 1993
34. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC, Lamberts SW: Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci 733:416-424, 1994
35. Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Fuger B, Li SR, Angelberger P, Raderer M, Wogritsch S, Kurtaran A, Kletter K, Dudczak R: Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 12 Suppl 2:S41-S45, 2001
36. Krenning EP, Kwekkeboom DJ PSKLRJ: Somatostatin receptor scintigraphy. Nuclear Medicine Annual1-50, 1995
37. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, Le GD: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38:853-858, 1997
38. Lebtahi R, Cadiot G, Mignon M, Le GD: Somatostatin receptor scintigraphy: a first-line imaging modality for gastroenteropancreatic neuroendocrine tumors. Gastroenterology 115:1025-1027, 1998
39. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125:26-34, 1996
40. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE, Jensen RT: Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112:335-347, 1997
41. Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, Doppman JL, Jensen RT: Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 40:539-553, 1999
42. Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Oberg K: [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 131:577-581, 1994
43. Kvols LK, Reubi JC, Horisberger U, Moertel CG, Rubin J, Charboneau JW: The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med 65:505-518, 1992
44. Strodel WE, Vinik AI, Jaffe BM, Eckhauser FE, Thompson NW: Substance P in the localization of a carcinoid tumor. J Surg Oncol 27:106-111, 1984
45. Feldman JM: Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem 32:840-844, 1986
46. Melmon KL, Sjoerdsma A, Oates JA, LASTER L: TREATMENT OF MALABSORPTION AND DIARRHEA OF THE CARCINOID SYNDROME WITH METHYSERGIDE. Gastroenterology 48:18-24, 1965
47. Alumets J, Hakanson R, Ingemansson S, Sundler F: Substance P and 5-HT in granules isolated from an intestinal argentaffin carcinoid. Histochemistry 52:217-222, 1977
48. Oates JA, Pettinger WA, Doctor RB: Evidence for the release of bradykinin in carcinoid syndrome. J Clin Invest 45:173-178, 1966
49. Wilander E, Grimelius L, Portela-Gomes G, Lundqvist G, Skoog V, Westermark P: Substance P and enteroglucagon-like immunoreactivity in argentaffin and argyrophil midgut carcinoid tumours. Scand J Gastroenterol Suppl 53:19-25, 1979
50. Lucas KJ, Feldman JM: Flushing in the carcinoid syndrome and plasma kallikrein. Cancer 58:2290-2293, 1986
51. Pernow B, WALDENSTROM J: Determination of 5-hydroxytryptamine, 5-hydroxyindole acetic acid and histamine in thirty-three cases of carcinoid tumor (argentaffinoma). Am J Med 23:16-25, 1957
52. Feldman JM: Increased dopamine production in patients with carcinoid tumors. Metabolism 34:255-260, 1985
53. Theodorsson-Norheim E, Norheim I, Oberg K, Brodin E, Lundberg JM, Tatemoto K, Lindgren PG: Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients. Biochem Biophys Res Commun 131:77-83, 1985
54. Vinik A: Endocrine tumors of the gastroenteropancreatic axis. In Diagnosis and Management of Endocrine-Related Tumors305, 1984
55. Feldman JM, O'Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 81:41-48, 1986
56. Vinik AI, Achem-Karam S, Owyang C: Gastrointestinal hormones in clinical medicine. Spec Top Endocrinol Metab 4:93-138, 1982
57. UDENFRIEND S, TITUS E, WEISSBACH H: The identification of 5-hydroxy-3-indoleacetic acid in normal urine and a method for its assay. J Biol Chem 216:499-505, 1955
58. Das ML: A rapid, sensitive method for direct estimation of serotonin in whole blood. Biochem Med 6:299-309, 1972
59. Waalkes T P: The determination of serotonin (5-hydroxtryptamine. in human blood. J Lab Clin Med 55:824-829, 1959
60. Won JG, Tseng HS, Yang AH, Tang KT, Jap TS, Lee CH, Lin HD, Burcus N, Pittenger G, Vinik A: Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS). Clin Endocrinol (Oxf) 65:566-578, 2006
61. Modlin IM: Carcinoid syndrome. J Clin Gastroenterol 2:349-354, 1980
62. Sandler M, Karim SM, Williams ED: Prostaglandins in amine-peptide-secreting tumours. Lancet 2:1053-1054, 1968
63. Aldrich LB, Moattari AR, Vinik AI: Distinguishing features of idiopathic flushing and carcinoid syndrome. Arch Intern Med 148:2614-2610, 1988
64. Ahlman H, Dahlstrom A, Gronstad K, Tisell LE, Oberg K, Zinner MJ, Jaffe BM: The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin. Ann Surg 201:81-86, 1985
65. Kaplan EL, Jaffe BM, Peskin GW: A new provocative test for the diagnosis of the carcinoid syndrome. Am J Surg 123:173-179, 1972
66. Eckhauser FE, Lloyd RV, Thompson NW, Raper SE, Vinik AI: Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery 104:1046-1053, 1988
67. Conlon JM, Deacon CF, Richter G, Stockmann F, Creutzfeldt W: Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 22:97-105, 1987
68. Norheim I, Theodorsson-Norheim E, Brodin E, Oberg K: Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 63:605-612, 1986
69. Voute PA, Hoefnagel CA, Marcuse HR, de KJ: Detection of neuroblastoma with 131I-meta-iodobenzylguanidine. Prog Clin Biol Res 175:389-398, 1985
70. Roberts WC: A unique heart disease associated with a unique cancer: carcinoid heart disease. Am J Cardiol 80:251-256, 1997
71. Anderson AS, Krauss D, Lang R: Cardiovascular complications of malignant carcinoid disease. Am Heart J 134:693-702, 1997
72. Callahan JA, Wroblewski EM, Reeder GS, Edwards WD, Seward JB, Tajik AJ: Echocardiographic features of carcinoid heart disease. Am J Cardiol 50:762-768, 1982
73. Lundin L, Landelius A, Oberg K: Transesophageal echocardiography improves the diagnostic value of cardiac ultrasound in patients with carcinoid heart disease. [article online], 1991.
74. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvols LK: Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 87:1188-1196, 1993
75. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581-588, 1997
76. Roberts WC: A unique heart disease associated with a unique cancer: Carcinoid heart disease. [article online], 1997.
77. Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK: Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 25:410-416, 1995
78. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E: Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 77:264-269, 1988
79. Ribiolio P, Wilson J HJSLBTFJ: Carcinoid heart disease, Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92:790-795, 1998
80. Perry RR, Vinik AI: Endocrine tumors of the gastrointestinal tract. Annu Rev Med 47:57-68, 1996
81. Lundin L, Oberg K, Landelius J, Hansson HE, Wilander E, Theodorsson E: Plasma atrial natriuretic peptide in carcinoid heart disease. Am J Cardiol 63:969-972, 1989
82. Rayson D, Pitot HC, Kvols LK: Regression of metastatic carcinoid tumor after valvular surgery for carcinoid heart disease. Cancer 79:605-611, 1997
83. Meijer WG, van d, V, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH: Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 44:184-191, 2003
84. Jacobsen MB, Hanssen LE: Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med 237:269-275, 1995
85. Eriksson B, Oberg K: Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 10 Suppl 2:S31-S38, 1999
86. Lipton A, Costa L, Ali S, Demers L: Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28:54-59, 2001
87. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001
88. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488-493, 1996
89. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785-1791, 1996
90. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854, 1999
91. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038-2044, 1998
92. Body JJ, Dumon JC, Piccart M, Ford J: Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. J Bone Miner Res 10:1191-1196, 1995
93. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002
94. Lee MV, Fong EM, Singer FR, Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602-2608, 2001
95. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949-2954, 2000
96. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62:2708-2714, 2002
97. Calis KA, Pucino F: Zoledronic acid and secondary prevention of fractures. N Engl J Med 357:1861-1862, 2007
98. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679-689, 2003
99. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA: Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169:1143-1149, 2003
100. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 100:10954-10959, 2003
101. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69, 2005
102. Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1:727-740, 1983
103. Godwin JD: Carcinoid tumors. An analysis of 2,837 cases. Cancer 36:560-569, 1975
104. Maton PN, Camilleri M, Griffin G, Allison DJ, Hodgson HJ, Chadwick VS: Role of hepatic arterial embolisation in the carcinoid syndrome. Br Med J (Clin Res Ed) 287:932-935, 1983
105. Gyr NE, Kayasseh L, Keller U: Somatostatin as a therapeutic agetn. In Gut Hormones. 2nd Ed. 2 ed. Bloom SR, Polak JM, Eds. Edinburgh, Churchill Livingstone, 1981, p. 581-585
106. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M: Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 48:50-53, 1979
107. Strodel WE, Strodel WE OT: Small bowel carcinoid tuimors and the carcinoid syndrome. Endocrine Surgery Update293, 1983
108. Kvols LK, Martin JK, Marsh HM, Moertel CG: Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 313:1229-1230, 1985
109. Vinik AI, Tsai ST, Moattari AR, Cheung P, Eckhauser FE, Cho K: Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med 81:23-40, 1986
110. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663-666, 1986
111. Richter G, Stockman F LBCJCW: Short-term administration of somatostatin analogue SMS-201-995 in patients with carcinoid tumors. Scand J Gastroenterol 21:193, 1986
112. Woltering EA, Mamikunian PM, Zietz S, Krutzik SR, Go VL, Vinik AI, Vinik E, O'Dorisio TM, Mamikunian G: Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas 31:392-400, 2005
113. Kvols LK, Martin JK, Marsh HM, Moertel CG: Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 313:1229-1230, 1985
114. Santangelo WC, O'Dorisio TM, Kim JG, Severino G, Krejs GJ: Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann Intern Med 103:363-367, 1985
115. Arnold R, Lankisch PG: Somatostatin and the gastrointestinal tract. Clin Gastroenterol 9:733-753, 1980
116. Stockmann F, Richter G LBCJCW: Long-term treatment of patients with endocrine gastrointestinal tumors with the somatostatin analogue SMS 201-995. Scand J Gastroenterol 21:230, 1986
117. Hengl G, Prager J, Pointner H: The influence of somatostatin on the absorption of triglycerides in partially gastrectomized subjects. Acta Hepatogastroenterol (Stuttg) 26:392-395, 1979
118. Poole CJ: Myelopathy secondary to metastatic carcinoid tumour. J Neurol Neurosurg Psychiatry 47:1359-1360, 1984
119. Berry EM, Maunder C, Wilson M: Carcinoid myopathy and treatment with cyproheptadine (Periactin). Gut 15:34-38, 1974
120. Green D, JOYNT RJ, VANALLEN MW: NEUROMYOPATHY ASSOCIATED WITH A MALIGNANT CARCINOID TUMOR. A CASE REPORT. Arch Intern Med 114:494-496, 1964
121. Wroe SJ, Ardron M, Bowden AN: Myasthenia gravis associated with a hormone producing malignant carcinoid tumour. J Neurol Neurosurg Psychiatry 48:719-720, 1985
122. Kraenzlin ME, Ch'ng JL, Wood SM, Carr DH, Bloom SR: Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88:185-187, 1985
123. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, Kelsen D: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72:244-248, 1993
124. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J: Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32:217-223, 1993
125. Janson ET, Oberg K: Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32:225-229, 1993
126. Kvols LK: Therapy of the malignant carcinoid syndrome. Endocrinol Metab Clin North Am 18:557-568, 1989
127. McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM: Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 15:132-153, 1985
128. Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, Carey JE, Swanson DP, Copp JE, Satterlee WG, .: Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 25:197-206, 1984
129. Sninsky CA, Wolfe MM, Martin JL, Howe BA, O'Dorisio TM, McGuigan JE, Mathias JR: Myoelectric effects of vasoactive intestinal peptide on rabbit small intestine. Am J Physiol 244:G46-G51, 1983
130. Lamberts SW, Krenning EP, Klijn JG, Reubi JC: The clinical use of somatostatin analogues in the treatment of cancer. Baillieres Clin Endocrinol Metab 4:29-49, 1990
131. Schubert ML: In vivo somatostatin receptor imaging in the detection and treatment of gastrointestinal cancer. Gastroenterology 100:1143-1144, 1991
132. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S: The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 147:149-154, 1986
133. Mekhjian HS, O'Dorisio TM: VIPoma syndrome. Semin Oncol 14:282-291, 1987
134. Nobin A, Mansson B, Lunderquist A: Evaluation of temporary liver dearterialization and embolization in patients with metastatic carcinoid tumour. Acta Oncol 28:419-424, 1989
135. Moertel CG: Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5:1502-1522, 1987
136. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, III, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D: Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13-23, 2007
137. Kennedy AS, Warner R: Radioembolisation for neuroendocrine hepatic metastases. Cancer Investigation 25:55-56, 2007
138. van Hazel GA, Rubin J, Moertel CG: Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine. Cancer Treat Rep 67:583-585, 1983
139. Moertel CG, Hanley JA: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2:327-334, 1979
140. Melia WM, Nunnerley HB, Johnson PJ, Williams R: Use of arterial devascularization and cytotoxic drugs in 30 patients with the carcinoid syndrome. Br J Cancer 46:331-339, 1982
141. Kvols LK, Buck M: Chemotherapy of endocrine malignancies: a review. Semin Oncol 14:343-353, 1987
142. Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinehart JJ, Eyre HJ, Rivkin SE, Fleming TR, Macdonald JS: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 73:1505-1508, 1994
143. Moertel CG, Rubin J, O'Connell MJ: Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treat Rep 70:1459-1460, 1986
144. Kelsen D, Fiore J HRCEMG: Phase II trial of etoposide in APUD tumors. Cancer Treat Rep 71:305-307, 1987
145. Mengel C E, Shaffer RD: The carcinoid syndrome. In Cancer Medicine 1973
146. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO, Jr.: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2:1255-1259, 1984
147. Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B, Costanzi JH: A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60:2891-2895, 1987
148. Oberg K, Norheim I, Alm G: Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. Eur J Cancer Clin Oncol 25:1475-1479, 1989
149. Feldman JM: Carcinoid tumors and the carcinoid syndrome. Curr Probl Surg 26:835-885, 1989
150. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
151. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
152. Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 17:596-603, 2005
153. Kiepe D, Ciarmatori S, Hoeflich A, Wolf E, Tonshoff B: Insulin-like growth factor (IGF)-I stimulates cell proliferation and induces IGF binding protein (IGFBP)-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes via distinct signaling pathways. Endocrinology 146:3096-3104, 2005
154. Ha CH, Bennett AM, Jin ZG: A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor. J Biol Chem 2008
155. Vignot S, Faivre S, Aguirre D, Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525-537, 2005
156. Smolewski P: Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17:487-494, 2006
157. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, viel-Ronen S, Tsao MS, Hedley D, Siu LL: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148-1154, 2006
158. Yao JC, Phan A, Chang DZ, Wolff RA, Jacobs C, Mares JE, Gupta S, Meric-Bernstam F, Rashid A: Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET) (Abstract). Journal of Clinical Oncology 25: 2007
159. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de OA, Jr., Dalino P, Salahuddin N, Korbonits M, Grossman AB: Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line. Neuroendocrinology 2007
160. Awada A, Cardoso F, Fontaine C, Dirix L, De GJ, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M: The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 44:84-91, 2008
161. Oberg K, Eriksson B: Medical treatment of neuroendocrine gut and pancreatic tumors. Acta Oncol 28:425-431, 1989
162. Hanssen LE, Schrumpf E, Kolbenstvedt AN, Tausjo J, Dolva LO: Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 24:787-795, 1989
163. Sisson J C, Hutchinson RJ JJ: Acute toxicity of therapeutic I-131-MIBG relates more to whole body than to blood radiation dosimetry. J Nucl Med 23:618, 1987
164. Oberg K: The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 3:35-41, 1992
165. Moertel CG, Rubin J, Kvols LK: Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7:865-868, 1989
166. Ajani J, Carrasco C CC: Islet cell tumors metastatic to the liver: effective palliation by seuential hepatic artery embolization. Proc Am Soc Clin Oncol 4:80, 1989
167. Moertel C G, May GR MJRJSA: Sequential hepatic artery occlusion (HAO. and chemotherapy for metastic carcinoid tumor and islet cell carcinoma. Proc Am Soc Clin Oncol 4:80, 1985